Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moksha8 Pharmaceuticals Announces Strategic Partnership with Janssen for Selected CNS Portfolio in Mexico","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","amount":"$44.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Methylphenidate

    Menu

    Methylphenidate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aytu BioPharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

              Details:

              Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

              Lead Product(s): Methylphenidate

              Therapeutic Area: Psychiatry/Psychology Product Name: Cotempla

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              KemPharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

              Details:

              Prodrug of d-methylphenidate, is sole API in KP1077, a potential first-ever therapeutic treatment for Idiopathic Hypersomnia, a neurological disorder marked by significant, detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.

              Lead Product(s): Methylphenidate

              Therapeutic Area: Sleep Product Name: KP1077

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neos Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement

              Details:

              Aytu adds Neos' established, multi-brand ADHD portfolio which includes Adzenys XR-ODT and Cotempla XR-ODT, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments.

              Lead Product(s): Methylphenidate

              Therapeutic Area: Psychiatry/Psychology Product Name: Cotempla XR-ODT

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Aytu BioScience

              Deal Size: $44.9 million Upfront Cash: Undisclosed

              Deal Type: Merger December 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moksha8 Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moksha8 Pharmaceuticals Announces Strategic Partnership with Janssen for Selected CNS Portfolio in Mexico

              Details:

              The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.

              Lead Product(s): Methylphenidate

              Therapeutic Area: Psychiatry/Psychology Product Name: Concerta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Veranova Methylphenidate
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Close
              4
              Post Enquiry
              POST ENQUIRY